Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | GFER | P55789 | 1/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.74 |
| ▸ | RELA | Q04206 | 1/20 | 0.74 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282481 | 0.90 | KDM4E (0.63) | XDHKDM4ELMNAPOLBGAA | |
| Gallic Acid Methyl Ester SCHEMBL39513 | 0.86 | KDM4E (1.00) | XDHKDM4ELMNAPOLBGAA | |
| SCHEMBL29742519 | 0.85 | POLB (0.58) | XDHKDM4ELMNAPOLBGAA | |
| SCHEMBL400542 | 0.85 | POLB (0.58) | XDHKDM4ELMNAPOLBGAA | |
| Gallic Acid Methyl Ester SCHEMBL28507408 | 0.84 | KDM4E (0.95) | XDHKDM4ELMNAPOLBGAA | |
| Gallic Acid Methyl Ester SCHEMBL21543905 | 0.84 | KDM4E (0.95) | XDHKDM4ELMNAPOLBGAA | |
| Gallic Acid Methyl Ester SCHEMBL21611341 | 0.84 | KDM4E (0.95) | XDHKDM4ELMNAPOLBGAA | |
| Gallic Acid Methyl Ester SCHEMBL28556619 | 0.84 | KDM4E (0.95) | XDHKDM4ELMNAPOLBGAA | |
| SCHEMBL14466473 | 0.83 | KDM4E (0.55) | XDHKDM4ELMNAPOLBGAA | |
| SCHEMBL402038 | 0.83 | KDM4E (0.55) | XDHKDM4ELMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| CN-116947856-A | EZH2 inhibitor and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-0584085-B1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5554606-A | THIENAMYCIN DERIVATIVES; PSEUDOMONAS | ZENECA LIMITED (GB) | 1996-09-10 | — | — | US | disclosed |
| US-5447925-A | Carbapenems with side-chain S; use to treat infections | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-09-05 | — | — | US | disclosed |
| US-5438052-A | Cephalosporin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0584085-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LIMITED (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0580632-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0544166-A2 | Cephalosporinderivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992017480-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992017479-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | XDH 1052/4885KDM4E 3515/4885LMNA 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.